ICECURE MEDICAL LTD (ICCM) Stock News

USA - Nasdaq - NASDAQ:ICCM - IL0011224156 - Common Stock

0.6642 USD

-0.03 (-3.91%)

Last: 12/12/2025, 8:00:01 PM

0.67 USD

+0.01 (+0.87%)

Pre-Market: 12/15/2025, 5:41:38 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ICCM Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: IceCure Medical

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

10 days ago - By: IceCure Medical

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

25 days ago - By: Benzinga - Mentions: PACS GNTA SCYX NCNA ...

12 Health Care Stocks Moving In Thursday's After-Market Session

26 days ago - By: IceCure Medical

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

a month ago - By: Benzinga

What's Next: Icecure Medical's Earnings Preview

2 months ago - By: Stocktwits

News Image

IceCure Medical’s Treatment For Low-Risk Breast Cancer In Women Aged 70 And Over Receives FDA Approval

a month ago - By: IceCure Medical

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

a month ago - By: IceCure Medical

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

a month ago - By: IceCure Medical

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

a month ago - By: IceCure Medical

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

a month ago - By: Zacks Investment Research - Mentions: ACHC

Acadia Healthcare (ACHC) Beats Q3 Earnings and Revenue Estimates

a month ago - By: IceCure Medical

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

2 months ago - By: IceCure Medical

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

2 months ago - By: IceCure Medical

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

2 months ago - By: IceCure Medical

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

3 months ago - By: IceCure Medical

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

3 months ago - By: IceCure Medical

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

3 months ago - By: IceCure Medical

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

3 months ago - By: IceCure Medical

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

4 months ago - By: The Motley Fool

IceCure Medical Advances FDA Review

4 months ago - By: The Motley Fool

IceCure (ICCM) Q2 2025 Earnings Call Transcript

4 months ago - By: Zacks Investment Research - Mentions: CODX

IceCure Medical Ltd. (ICCM) Q2 Earnings Surpass Estimates

4 months ago - By: IceCure Medical

IceCure Reports Financial & Operational Results for the First Half of 2025

4 months ago - By: Zacks Investment Research - Mentions: VTRS

Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates

4 months ago - By: IceCure Medical

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

5 months ago - By: IceCure Medical

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

5 months ago - By: IceCure Medical

IceCure Announces Commencement of Rights Offering

5 months ago - By: IceCure Medical

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

6 months ago - By: IceCure Medical

IceCure Announces Record Date for Rights Offering for Up to $10 Million

6 months ago - By: IceCure Medical

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes